Johnson & Johnson says FDA grants Fast Track designation to nipocalimab

Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult patients with moderate-to-severe Sjogren’s disease, having previously been granted Breakthrough Therapy designation for the investigational therapy late last year. Currently, no advanced therapies are approved to treat this disease.